The completion of the largest-ever immunotherapy clinical trial on solid tumors such as nasopharyngeal cancer (NPC) is paving the way for a new era in precision immunotherapy for the future in cancer care.
This is despite the study having ended without an overall survival benefit - the gold standard primary end point in cancer clinical trials - which provides confirmed evidence that a given treatment extends life.
Called Vance, the global, multinational, randomized phase three trial, led by Singapore clinician-scientist Toh Han Chong, is the largest completed trial on T-cell therapy on any solid tumor.
"We are proud of the fact that it was the world's largest... I think it really is a testament to the remarkable work done by my colleagues, especially in a biotech company. These were the actual people making the T-cells in Singapore, so it's kind of a made-in-Singapore triumph," said Professor Toh, who is also deputy chief executive officer of strategic partnerships at the National Cancer Centre Singapore (NCCS).
Solid tumors are abnormal masses of tissue formed in specific organs such as the breasts, brain and upper part of the throat, or nasopharynx.
The Vance study looked at cancer of the nasopharynx since Prof Toh and his team at NCCS have been driving research to develop novel ways to treat Asian-endemic cancers.
NPC is common in males in Singapore and southern China, with an incidence of 8.9 per 100,000 males and 25 per 100,000 males, respectively.
Well-known NPC sufferers include Malaysian badminton star and three-time Olympic silver medalist Lee Chong Wei and South Korean actor Kim Woo-bin.
The current mainstay treatment of early and locally advanced NPC is radiotherapy and chemoradiotherapy, but once it spreads beyond the originating site, treatment is largely not curative, with the median survival currently at 21 to 29 months.
この記事は The Straits Times の November 14, 2024 版に掲載されています。
7 日間の Magzter GOLD 無料トライアルを開始して、何千もの厳選されたプレミアム ストーリー、9,000 以上の雑誌や新聞にアクセスしてください。
すでに購読者です ? サインイン
この記事は The Straits Times の November 14, 2024 版に掲載されています。
7 日間の Magzter GOLD 無料トライアルを開始して、何千もの厳選されたプレミアム ストーリー、9,000 以上の雑誌や新聞にアクセスしてください。
すでに購読者です? サインイン
AN ADDS CHINA MASTERS TO OLYMPIC CROWN
Fourth 2024 title cements her world No. 1 status; men's No. 3 Antonsen gets his fifth
The Taiwanese quintet's almost three-hour gig saw each member having his moment at the comeback show
2024 ENERGY IMMINENT LIVE IN SINGAPORE
Matcha shortage in Japan hits Singapore
Some shops here have raised prices on matcha products by 10 to 15 per cent since mid-October
Yan Huichang dazzles in guest conductor stint with SCO
Every concert needs to be special. That seems to be the credo of Cultural Medallion recipient Yan Huichang, who is the artistic director and principal conductor for life of the Hong Kong Chinese Orchestra (HKCO).
Iran director in exile says 'bittersweet' to represent Germany at Oscars
Forced to flee Iran, dissident director Mohammad Rasoulof says it is bittersweet that his latest movie will contend at the Oscars under the banner of another country.
Silent films get new reel at London haven
The black-and-white silent movie flickered into life as the pianist started up with a dramatic flourish.
Strong start for Wicked, Gladiator II in box-office battle
Musical adaptation Wicked and action epic Gladiator II generated a combined US$25.7 million (S$34.6 million) from early screenings in America and Canada, setting off the biggest box-office battle since \"Barbenheimer\" - the 2023 movie phenomenon that saw Barbie and Oppenheimer open on the same day.
Canada's PM Justin Trudeau spotted dancing at Taylor Swift concert in Toronto
Canadian Prime Minister Justin Trudeau (right) shook it off at American superstar Taylor Swift's Eras Tour in Toronto, Canada.
Best New Director nod for Singaporean film-maker Chiang Wei Liang
Golden Horse Awards 2024
Thinking of job options for my grown-up child with special needs
The goal does not always have to be employment. What is more important is participating in the world